-
Mashup Score: 9You and Whose Army? - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Oncs, Latest HeadlinesTweet-
Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial @OncJournal https://t.co/qJjf9rVXwH
-
-
Mashup Score: 1Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Oncs, Latest HeadlinesTweet-
This dovetails with our other recent work, finding that oncologists who receive more industry money seem more likely to be selected for NCCN guidelines committees 4/ @DusetzinaS @AaronWinn2 @DeyPranam https://t.co/OX4DJzcCrT
-
-
Mashup Score: 0Fare Thee Well - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In January, Oxford University Press will proudly welcome The Oncologist within its esteemed ranks. Thank you to our dedicated editors, devoted reviewers, authors, and our loyal readership who were part of this history and made this journal possible. https://t.co/zkgz6akQxL https://t.co/5jBbDDLODa
-
-
Mashup Score: 0HER2 Splice Site Mutation c.1899‐1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2‐Positive Gastric Adenocarcinoma - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
HER2 Splice Site Mutation c.1899‐1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2‐Positive Gastric Adenocarcinoma https://t.co/8tc8XIu2vB https://t.co/46nNbVoPit
-
-
Mashup Score: 1
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma #SystemicTherapy #TreatmentSequencing #RandomizedControlledTrials #GastrointestinalCancer https://t.co/iF9dKRtrjJ https://t.co/mbS6hOWcTd
-
-
Mashup Score: 2The Oncologist - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Finding a way for newly diagnosed cancer patients to access supportive care earns Dr. Enrique Soto Pérez de Celis (@EnriqueSoto8) The Oncologist journal’s 2021 Young Investigator Award. Read more about him and his research - https://t.co/x7lSdu2Rui. https://t.co/zhPAvaeaKJ https://t.co/r2eFz4JZp6
-
-
Mashup Score: 0Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review #NeuroendocrineTumors #Chemotherapy #Temozolomide #Capecitabine #GastrointestinalCancer https://t.co/azbPzlHZGV https://t.co/h253jjnuqJ
-
-
Mashup Score: 2Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population‐Based Analysis - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population‐Based Analysis #NonmetastaticColorectalCancer #SEER #ColorectalCancer #CRC https://t.co/UHQNcTEufX https://t.co/3WoXGb9dRE
-
-
Mashup Score: 2The Oncologist - 2 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer #EMERALDtrial #elacestrant #breastcancer https://t.co/XSxuCGM0Fk https://t.co/UYZ2bNY1ah
-
I’ll start: https://t.co/wZ6NR8IGUq